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Abstract The amygdala is essential for generating emo-
tional-affective behaviors. It consists of several nuclei with
highly selective, elaborate functions. In particular, the
central extended amygdala, consisting of the central
amygdala (CEA) and the bed nucleus of the stria terminalis
(BNST) is an essential component actively controlling
efferent connections to downstream effectors like
hypothalamus and brain stem. Both, CEA and BNST
contain high amounts of different neuropeptides that sig-
nificantly contribute to synaptic transmission. Among
these, neuropeptide Y (NPY) has emerged as an important
anxiolytic and fear-reducing neuromodulator. Here, we
characterized the expression, connectivity and electro-
physiological function of NPY and Y2 receptors within the
CEA. We identified several NPY-expressing neuronal
populations, including somatostatin- and calretinin-ex-
pressing neurons. Furthermore, in the main intercalated
nucleus, NPY is expressed primarily in dopamine D1
receptor-expressing neurons but also in interspersed
somatostatin-expressing neurons. Interestingly, NPY neu-
rons did not co-localize with the Y2 receptor. Retrograde
tract tracing experiments revealed that NPY neurons
reciprocally connect the CEA and BNST. Functionally, the
Y2 receptor agonist PYY3-36, reduced both, inhibitory as
well as excitatory synaptic transmission in the centrome-
dial amygdala (CEm). However, we also provide evidence
that lack of NPY or Y2 receptors results in increased
GABA release specifically at inhibitory synapses in the
CEm. Taken together, our findings suggest that NPY
expressed by distinct populations of neurons can modulate
afferent and efferent projections of the CEA via presy-
naptic Y2 receptors located at inhibitory and excitatory
synapses.
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Introduction
Neuropeptide Y (NPY) is a 36-amino acid peptide that is
widely distributed in the central nervous system. It is
particularly known for its involvement in the regulation of
appetite, pain perception and maintenance of energy
homeostasis, but also for its anxiolytic properties. Recently
an involvement in models of conditioned fear has been also
demonstrated (Broqua et al. 1995; Fendt et al. 2009; Gut-
man et al. 2008; Lach and de Lima 2013; Verma et al.
2012). NPY acts through at least five different G protein-
coupled receptors (Y1, Y2, Y4, Y5 and y6) that in general
exert a prolonged inhibitory action (Michel et al. 1998). In
the CNS, postsynaptic Y1 and predominantly presynaptic
Y2 receptors are the most abundant (Roder et al. 1996;
Electronic supplementary material The online version of this
article (doi:10.1007/s00429-015-1107-7) contains supplementary
material, which is available to authorized users.
& R. O. Tasan
ramon.tasan@i-med.ac.at
1 Department of Pharmacology, Medical University Innsbruck,
Peter-Mayr-Strasse 1a, 6020 Innsbruck, Austria
2 Capes Foundation, Ministry of Education of Brazil, Brası´lia,
DF 70040-020, Brazil
3 Janssen Research & Development, LLC, San Diego, CA,
USA
4 Neuroscience Division, Garvan Institute of Medical
Research, Darlinghurst, Sydney, NSW 2010, Australia
5 Institute of Physiology I (Neurophysiology), Westfa¨lische
Wilhelms-Universita¨t, Munster, Germany
123
Brain Struct Funct (2016) 221:3373–3391
DOI 10.1007/s00429-015-1107-7
Dumont et al. 1996). NPY and Y2 receptors are particu-
larly enriched in the hippocampus and hypothalamus, but
also in the central extended amygdala (Gray and Magnuson
1992; Stanic et al. 2011).
The amygdala consists of several different nuclei and
controls emotional-affective behaviors such as fear and
anxiety (Pape and Pare 2010; Sah et al. 2003). The central
nucleus of the amygdala (CEA) is not only the major
output station of the amygdala but consists itself of a highly
complex micro-network capable of diverse types of plas-
ticity (Ciocchi et al. 2010; Haubensak et al. 2010; Li et al.
2013; Wilensky et al. 2006). The CEA can be divided into
at least 3 distinct subnuclei, namely the centromedial
(CEm), centrolateral (CEl) and centrocapsular (CEc)
nucleus. The main amygdala output originates from the
CEm and consists of GABAergic neurons with efferent
projections targeting different effector brain regions,
including hypothalamus, brainstem and bed nucleus of the
stria terminalis (BNST) (Dong et al. 2001; LeDoux et al.
1988). Interestingly, CEA neurons express high concen-
trations of different neuropeptides. Ample evidence sug-
gests that these neuropeptides are significantly shaping the
overall emotional response generated by the amygdala
(Bowers et al. 2012; Gutman et al. 2008; Heilig et al. 1994;
Heilig 2004; Tasan et al. 2010). In the BNST, Y2 receptors
have been demonstrated to significantly reduce the fre-
quency of miniature inhibitory postsynaptic currents
(mIPSC), indicating their presynaptic localization on
inhibitory neurons (Kash and Winder 2006).
As both, the CEA and BNST, are components of the
central extended amygdala and thus exhibit considerable
neuroanatomical analogies, we hypothesized that Y2
receptors in the CEA would reduce inhibitory input by a
similar mechanism. To shed more light on the NPY and Y2
receptor-dependent micro-network within the CEA we
utilized wildtype and various germline knock-out models,
combined with slice electrophysiology, neuronal tract-
tracing and immunohistochemistry. We illustrate here the
exact localization as well as the afferent and efferent pro-
jections of NPY and Y2 receptor containing neurons of the
CEA. Furthermore, we demonstrate that presynaptic Y2
receptors are crucially involved in the regulation of both,
GABA and glutamate release onto CEm neurons.
Experimental procedures
Animals
All procedures involving animals and animal care were
conducted in accordance with international laws and poli-
cies (Directive 2010/63/EU of the European parliament and
of the council of 22 September 2010 on the protection of
animals used for scientific purposes; Guide for the Care
and Use of Laboratory Animals, US National Research
Council, 2011) and were approved by the Austrian Min-
istry of Science. All efforts were taken to minimize the
number of animals used and their suffering.
All experiments were performed in adult male mice
(10–16 weeks old, weighing 25–30 g) maintained on a
pure C57BL/6N background (Charles River, Sulzfeld,
Germany). Germline knock-out mice for the Y2 receptor
(Y2KO) as well as NPYKO mice were backcrossed to a
C57BL/6N background for at least 10 generations. Mice
were housed in groups of 3–5 animals under standard
laboratory conditions (12 h/12 h light/dark cycle, lights
being on at 07:00, food and water ad libitum). Generation
of NPYKO mice and Y2KO mice has been described in
detail previously (Sainsbury et al. 2002; Verma et al.
2012). For immuolabeling procedures and electrophysio-
logical recordings specifically from NPY neurons, we used
an NPY-GFP mouse line that expresses GFP from the NPY
promoter (B6.FVB-Tg(Npy-hrGFP)1Lowl/J). This trans-
genic mouse line was characterized previously (van den
Pol et al. 2009) and we confirmed the identity of GFP
neurons by dual immunofluorescence of hrGFP and
endogenous NPY (Fig. 1).
Electrophysiology
Acute brain slice preparation
Adult male mice were anesthetized with isoflurane (Baxter,
Austria), decapitated and the brain was rapidly removed,
hemisected and placed in ice-cold oxygenated (95 % O2/
5 % CO2) artificial cerebrospinal fluid (aCSF) containing
(in mM) 126 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1 MgCl2, 26
NaHCO3, 2 CaCl2 and 10 glucose. Coronal brain slices
(300 lm thick) containing the CEm (3–4 sections per
mouse) and Im (1–2 sections per mouse) were cut using a
vibratome (VT1200, Leica Microsystems, Germany). Sli-
ces were allowed to recover for at least 1 h in aCSF before
being transferred to a recording chamber constantly per-
fused with aCSF and gradually warmed to the recording
temperature of 32–34 C.
Electrophysiological recordings
For whole-cell voltage-clamp recordings (holding poten-
tial = -70 mV) of inhibitory and excitatory postsynaptic
currents (IPSCs and EPSCs, respectively), recording pip-
ettes with a final tip resistance of 2–5 MX were pulled
using a micropipette puller (P-1000, Sutter Instrument,
USA) and filled with solution containing (in mM) 135.0
CsCl, 10.0 CsOH-HEPES, 0.2 CsOH-EGTA, 2.0 Mg-ATP,
0.3 Na3-GTP, 8.0 NaCl and 5.0 lidocaine N-ethyl bromide
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(QX-314) for sIPSCs; or 117.5 Cs-gluconate, 17.5 CsCl,
8.0 NaCl, 10.0 CsOH-HEPES, 0.2 CsOH-EGTA, 2.0
MgATP, 0.3 Na3-GFP and 5.0 QX-314 for sEPSCs. For
whole-cell current-clamp recordings (holding current = 0
pA), the pipette solution contained (in mM) 122.5 K-glu-
conate, 12.5 KCl, 10.0 KOH-HEPES, 8.0 NaCl, 0.2 KOH-
EGTA, 2.0 MgATP and 0.3 Na3GTP. Im neurons were
identified using NPY-GFP mice (see Fig. 3). Evoked
inhibitory postsynaptic currents were measured in voltage-
clamp configuration in response to electrical stimulation
(20–150 lA: set to the minimum current required to con-
sistently evoke responses, i.e.,[90 % success rate) of
medial inputs to the CEm. Electrical stimulations were
delivered using a concentric, bipolar platinum/iridium
electrode with a 2–3 lm tip diameter (MicroProbes, USA)
connected to a constant current stimulator (Digitimer, UK).
Neurons of the CEm were visually identified based on their
anatomical location using an upright microscope (BX51,
Olympus, Japan) equipped with a 409 water immersion
objective, infrared light with differential interference con-
trast and a digital camera. For recordings of IPSCs AMPA
and NMDA glutamate receptors were blocked using 10 lM
6,7-dinitroquinoxaline-2,3-dione (DNQX) and 100 lM
DL-2-amino-5-phosphonopentanoic acid (DL-AP5;
Abcam, UK), respectively. GABAA receptors were blocked
with 100 lM picrotoxin (Tocris Bioscience, UK). PYY3-36
(50–100 nM, Polypeptide, Strasbourg, France) and JNJ-
31020028 (1 lM, Janssen Research & Development, LLC,
San Diego, USA) were dissolved in aCSF containing DL-
AP5 and DNQX or picrotoxin and administered by bath
application. Compared to NPY3-36, PYY3-36 shows similar
affinity and specificity for Y2 receptors, it is, however, less
prone to adsorption to the tubing and thus better suited for
slice electrophysiology experiments. Nonetheless, only 1
Fig. 1 Validation of the NPY-GFP mouse. a Photomicrograph of
NPY immunoreactivity and b NPY-GFP immunoreactivtiy in coronal
brain sections of an NPY-GFP mouse compared to, c autoradiograph
of an in situ hybridization for NPY mRNA, demonstrating an
overlapping distribution pattern of NPY mRNA and NPY-GFP. Dual
immunohistochemistry exemplified in the CEm for d NPY, e NPY-
GFP and f overlay demonstrates extensive co-localization (note the
arrows in a–c displaying similar distribution of cell bodies in the
basolateral amygdala (BLA), main intercalated nucleus (Im) and
reticular thalamic nucleus (RT) of NPY-GFP and NPY mRNA
labeling compared to NPY-IR that is frequently confined to axons and
axon terminals—arrowheads). Scale bars a–c 1 mm, d–f 100 lm
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cell was recorded per slice in case complete washout could
not be achieved. The D1 receptor agonist (A68930,
500 nM, Tocris, UK) was dissolved in aCSF containing
DL-AP5, DNQX and picrotoxin. Cells exhibiting[20 %
changes in access resistance or holding current were
excluded from analysis. Data were filtered at 2.9 kHz and
sampled at 10 kHz with an EPC10 patch-clamp amplifier
and analyzed using PatchMaster and FitMaster software
(HEKA Electronic, Germany) and Minianalysis (Synap-
tosoft, USA). For analysis of sIPSCs and sEPSCs, baseline
events were recorded for 2 min prior to PYY3-36 and JNJ-
31020028 application and compared with the final 2 min of
drug application (4–6 min after wash-in). All events from
the respective time periods were analyzed and averaged for
each cell.
Neuronal tract tracing
To identify NPY containing neurons that reciprocally
connect CEm and BNST, the retrograde neuronal tracer
hydroxystilbamidine (1 % Fluorogold, FG, Fluorochrome
LLC, USA) was injected unilaterally into the CEm or
BNST of deeply anesthetized, male, 8–12 weeks old
NPY-GFP mice (3 NPY-GFP mice for CEA injections
and 3 NPY-GFP mice for BNST injections). Neuronal
tracers (0.2 ll) were pressure injected by glass cannulas
connected to a pneumatic pressure-injector (Toohey-
Spritzer, Science products, Germany) using the following
coordinates for the CEA and BNST (in mm, from
bregma): CEA: A, -1.0; L, ±2.8; V, -4.9; BNST: A,
0.0; L, ± 1.0; V, -4.6. One week after injections, mice
were deeply anesthetized by a lethal dose of thiopental
(Thiopental, Sandoz, Austria) and transcardially perfused
with ice-cold 4 % PFA (10 min, 9 ml/min). Brains were
postfixed for 90 min in the same solution, cryoprotected
by immersion into 20 % sucrose (24 h) and snap-frozen
in isopentane (-70 C, 3 min).
Histochemistry
For in situ hybridization and receptor autoradiography
20 lm coronal sections from snap-frozen mouse brains
were used.
In situ hybridization
Oligonucleotides (2.5 pmol) were 30 end-labeled using
[35S]a-dATP (50 lCi; 1300 Ci/mmol, Hartmann Analytic
GmbH, Braunschweig, Germany) with terminal transferase
(Roche Diagnostics, Basel, Switzerland) and incubated on
20 lm coronal brain sections, as described previously in
detail (Tasan et al. 2010, 2011).
Y2 receptor autoradiography
C-terminally truncated human peptide YY (hPYY3-36) was
radiolabeled with Na125I (2200 Ci/mmol; PerkinElmer,
Boston, USA), and brain sections were incubated with the
radiolabeled peptide as described in detail previously
(Tasan et al. 2009).
Tissue preparation
For immunohistochemical co-labeling in total 8 NPY-GFP
mice were used. Mice were killed by injecting a lethal dose
of thiopental (Thiopental, Sandoz, Austria) and brains were
perfused with 4 % paraformaldehyde (PFA) for immuno-
histochemistry (Tasan et al. 2010).
Immunohistochemistry
Antibodies for NPY and somatostatin were produced in-
house and have been validated previously (Bellmann et al.
1991; Sperk and Widmann 1985). Furthermore, a detailed
characterization for the NPY-GFP mouse and the respective
hrGFP antibody (Fig. 1) as well as antibodies for the Y2
receptor (Fig. 4) and GABA (Supplementary Fig. 1) is
included in this study. Immunohistochemical analyses were
performed on free-floating, PFA-fixed, 40-lm-thick coronal
sections using indirect peroxidase labeling, as described
previously (Tasan et al. 2011). In brief, coronal sectionswere
incubated free floating in 10 % normal horse or goat serum
(Biomedica, Vienna, Austria) in Tris–HCl buffered saline
(TBS; 50 mM, pH 7.2) for 90 min, followed by incubation
with primary antiserum (Table 1). The resulting complex
was visualized by incubation with horseradish peroxidase
(HRP)-coupled secondary antibody (1:250 P0448; Dako,
Vienna, Austria) at room temperature for 150 min. For
immunofluorescence sections were incubated in a tyramide
signal amplification solution (1:100, TSA fluorescein, in-
house) for 3–8 min. After staining, sections were exposed to
0.01 M HCl for 20 min at room temperature to denature
HRP and antibodies or incubated with 3 %H2O2 to denature
HRP peroxidase followed by incubation with a second
antibody as described before except that staining was per-
formed with TSA AMCA (1:100, in-house). NPY-GFP was
visualized by endogenous fluorescence or by a secondary
antibody conjugated to an Alexa-Fluor 488 dye (Molecular
Probes, A21206, 1:1000). Sections were mounted on slides
and covered using Vectashield mounting medium (Vector
laboratories, Inc., Burlingame, USA).
Quantification of immunohistochemical labeling
Analysis of dual labeling immunofluorescence was done as
described elsewhere (McDonald and Mascagni 2010;
3376 Brain Struct Funct (2016) 221:3373–3391
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Tasan et al. 2011). In brief, photomicrographs were taken
on a fluorescent microscope (Zeiss Axio Imager M1)
equipped with a halogen light source, respective filter sets
and a Hamamatsu monochrome camera (Hamamatsu
ORCA ER C4742-80-12AG). The numbers of NPY-GFP,
SST, CR and FG labeled cells were obtained bilaterally
from 3–4 sections per animal depicting the central amyg-
dala or BNST at a magnification of 400 times in multiple
separate fields. Results are presented as total numbers and
percentages of NPY-GFP-positive, single- and dual-labeled
cells.
Statistical analysis
Data are presented as mean ± SEM. They were analyzed
for normal distribution and equal variances using GraphPad
Prism software (Prism 5 for Macintosh, GraphPad Software
Inc., San Diego, CA). Electrophysiological data were
analyzed using the paired t test, one-way or two-way
ANOVA followed by Bonferroni post hoc test.
Results
Distribution of NPY and Y2 receptors in the central
extended amygdala and intercalated neurons
Since NPY is predominantly expressed in axons and axon
terminals, we used a transgenic mouse line [B6.FVB-
Tg(Npy-hrGFP)1Lowl/J] that expresses GFP in somata of
NPY-expressing neurons. This mouse line was character-
ized previously (van den Pol et al. 2009) and we confirmed
the validity for this study by dual immunofluorescence of
hrGFP and endogenous NPY. As shown in Fig. 1, the
overall distribution of NPY-IR and NPY-GFP was highly
similar (Fig. 1a, b) exhibiting extensive co-localization,
here exemplified in a higher magnification photomicro-
graph for the CEA (Fig. 1d–f). Importantly, labeling of
NPY-GFP cell bodies corresponded better to the in situ
hybridization for NPY mRNA than immunoreactivity with
an NPY antibody (Fig. 1a–c), consistent with the expres-
sion of the NPY peptide in axons and axon terminals
compared to NPY-GFP expression in cell bodies (note the
highly similar expression of NPY mRNA and NPY-GFP,
but only weak labeling of NPY-IR in the reticular thalamic
nucleus (RT) and in the main intercalated nucleus of the
amygdala (Im) as well as a higher number of NPY-GFP
cell bodies in the basolateral amygdala (BLA), arrows in
Fig. 1a–c). Virtually all NPY-GFP-positive neurons in the
BLA, CEA and adjacent intercalated neurons were co-lo-
calized with the inhibitory neurotransmitter GABA
(Fig. 2a–g), confirming that NPY in the amygdala is
expressed predominantly by GABAergic neurons. The
specificity of the GABA antibody has been demonstrated
previously by us and others (Busti et al. 2011; Menegola
et al. 2008; Tasan et al. 2011) and the immunohisto-
chemical protocol for the present study was validated by
comparing GABA immuno-labeling to an in situ
hybridization for the GABA synthesizing enzyme GAD67
(Supplementary Fig. 1a, b) as well as by dual
Table 1 List of primary antibodies
Primary antibody Species Code Source Characterization Dilution
Calretinin Goat AB1550 Chemicon WB, IHC 1:500
Calretinin Rabbit 7697 Swant WB, IHC, no labeling in knock-out mice 1:1000
Dopamine 1 receptor Goat Af1000 Frontier
Institute,
Japan
WB, IHC, Narushima et al. (2006) 1:1000
Fluorogold Rabbit AB153 Millipore IHC, no labeling in non-injected mice (this study) 1:2000
GABA Rabbit A2052 Sigma-Aldrich IHC, dual labeling with GAD67, Comparison to in situ




Mouse MAB5406 Chemicon WB, IHC, comparison to in situ hybridization (this study) 1:5000
Humanized Renilla
reniformis GFP
Rabbit 240141 Agilent IHC, dual IHC with NPY in NPY-GFP mice, no labeling in wild-
type mice (this study)
1:200
Neuropeptide Y Rabbit (1-5) Bellmann et al.
(1991)
HPLC, RIA, IHC, no labeling in knock-out mice 1:2000
Somatostatin Rabbit 14 (2-5) Sperk et al.
(1985)
HPLC, RIA, IHC 1:2000
Y2 receptor Rabbit RA14112 Neuromics IHC, comparison to in situ hybridization and receptor binding,
no labeling in knock-out mice (this study)
1:2000
WB Western blot, IHC immunohistochemistry, HPLC high-performance liquid chromatography, RIA radio-immuno assay
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immunohistochemistry for GAD67 and GABA (Supple-
mentary Fig. 1c–e).
NPY in the CEA
As shown in Fig. 2, NPY-GFP-positive neurons and dense
fiber staining were observed predominantly in the centro-
medial amygdala (CEm), with only few neurons and fibers
in the centrolateral part (CEl, Fig. 2b, e, i). A considerable
portion of NPY-GFP-positive perikarya in the CEA was
co-localized with somatostatin (SST) (Fig. 2h–k). As
shown in Table 2, 41.5 % (139/335), 35.4 % (35/99), and
49.0 % (102/208) of NPY-GFP neurons were also
immuno-positive for SST in the CEm, CEc and CEl,
respectively.
However, some NPY-expressing neurons in the CEm
co-localized with the calcium-binding protein, calretinin
(CR) (Fig. 2l-o). As summarized in Table 3, 3.4 % of the
Fig. 2 Expression of NPY in different neurons of the CEA. a–
c NPY-GFP expression is evident in GABAergic neurons of the
basolateral (BLA) and centromedial amygdala (CEm) and also in the
lateral (lITC) and medial intercalated cells (mITC) and particularly in
the main intercalated nucleus (Im). Note the NPY-GFP-positive fibers
connecting the mITC and Im (blue arrowheads). d–f Higher mag-
nification of NPY-GFP neurons in the Im and CEm co-localized with
GABA and g higher magnification of a dual-labeled GABA/NPY-
GFP neuron (white arrow) in the CEm (a single-labeled GABA
neuron is marked with a red arrow). Note the dense, multi-layered
accumulation of NPY-GFP neurons in the Im. h–j The majority of
NPY-GFP neurons in the CEm co-express somatostatin (SST). Note
the relative absence of NPY-GFP in the centrolateral amygdala, CEl
and k higher magnification of a dual-labeled SST/NPY-GFP neuron
in the CEm (white arrow). l–n An additional group of NPY neurons
(green) in the CEm co-expresses the calcium-binding protein,
calretinin (red) (nuclear staining in blue (Hoechst)) and o higher
magnification of a dual-labeled CR/NPY-GFP neuron (white arrow)
and NPY-GFP (green arrow) and CR (red arrow) single-labeled
neurons. White arrows indicate examples of dual-labeled neurons.
Scale bars a–c, d–f, h–j, l–m 200 lm and in g, k, o 20 lm
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NPY-GFP neurons (16/476) in the CEm co-labeled for CR.
The number of CR neurons in the CEc and CEl was not
determined because dense fiber labeling made a discrimi-
nation of CR-positive cell bodies impossible. Interestingly,
CR and NPY, but not SST-positive fibers were also
observed in the stria terminalis, the main output fiber tract
originating from the CEm, suggesting the expression of
NPY on projection neurons and local neurons.
NPY in the intercalated nuclei
Intercalated neurons are a group of GABAergic neurons
surrounding the BLA and CEA (Busti et al. 2011). These
cell clusters send considerable projections to different CEA
subdivisions and are considered to have a crucial role in
fear and extinction learning (Amano et al. 2010; Verma
et al. 2015). Thus, we also analyzed the expression of NPY
and Y2 receptors in intercalated nuclei that may constitute
a potential source of NPY-ergic afferences to the CEA.
Interestingly, a distinct distribution was observed in the
intercalated nuclei. The main intercalated nucleus (Im) was
heavily populated by NPY-GFP-positive neurons, and
considering the different expression levels of NPY-GFP,
consisted of at least two populations of NPY-expressing
neurons (Fig. 3a). The vast majority of NPY-expressing
neurons in the Im were also positive for the dopamine D1
receptor (D1R) (Fig. 3a–f), while only a few, interspersed
NPY-expressing neurons contained SST (i–n). Interest-
ingly, compared to SST neurons, D1R-expressing neurons
of the Im exhibited lower expression of NPY-GFP (Fig. 3a,
i). Furthermore, NPY-GFP cells in the Im were densely
packed and in our 40-lm sections organized in multiple
overlapping layers making reliable quantification impossi-
ble. Thus, to corroborate our finding that the D1R is
expressed on NPY-expressing neurons of the Im, we
obtained electrophysiological recordings from GFP-ex-
pressing Im neurons in brain slices prepared from NPY-
GFP mice. Whole-cell current-clamp recordings targeting
GFP-expressing Im neurons demonstrated that bath appli-
cation of the selective D1R agonist, A68930, resulted in a
marked and reversible hyperpolarization of the resting
membrane potential from -75.90 ± 1.0 mV to
-79.05 ± 1.5 mV (Fig. 3g–h), indicating that the D1R is
expressed postsynaptically by neurons of the Im and con-
sistent with a previous study showing that dopamine
hyperpolarizes medial and lateral intercalated cells (Mar-
owsky et al. 2005). On the other hand, in the medial
(mITC) and lateral (lITC) clusters only a few NPY-ex-
pressing neurons were discovered (Fig. 2a–c).
Y2 receptors in the CEA
As shown in Fig. 4, the Y2 receptor antibody exhibited a
similar pattern of distribution as radioactive receptor
binding using the Y2 receptor preferring ligand
[125I]PYY3-36 and was comparable to in situ hybridiza-
tion for Y2 mRNA, emphasizing the presynaptic
expression of Y2 receptors. Importantly, in Y2KO mice
receptor binding with [125I]PYY3-36 as well as Y2
receptor immunoreactivity was absent (Fig. 4d, i and e,j),
confirming the specificity of the Y2 receptor immuno-
histochemistry protocol employed in our experiments
(note the residual labeling of cell nuclei and somata in
Y2KO mice frequently misinterpreted as Y2 receptor
immunolabeling, in Fig. 4e, j). Similar to NPY, Y2
receptor immunoreactivity (IR) was dense in the CEm,
but virtually absent from the CEl (Fig. 5a–f). Interest-
ingly, cell nuclei stained with Hoechst were surrounded
by Y2R-IR (Fig. 5g), suggesting Y2 receptor containing
terminals contact CEm somata. No co-localization with











Centrolateral 106 356 102 49.0 % (102/208) 22.3 % (102/458)
Centromedial 196 628 139 41.5 % (139/335) 18.1 % (139/767)
Centrocapsular 64 255 35 35.4 % (35/99) 12.1 % (35/290)











Centrolateral n.d. n.d. n.d. n.d. n.d.
Centromedial 460 382 16 3.4 % (16/476) 4.0 % (16/398)
Centrocapsular n.d. n.d. n.d. n.d. n.d.
n.d. not done, because the calretinin antibodies labeled there only fibers but no cell bodies
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NPY-GFP was observed (Fig. 5h–o). At higher magnifi-
cation, a clear distinction between NPY-GFP and Y2R
containing fibers was observed; however, both were
allocated around cell bodies in the CEm (Fig. 5k, o).
Moreover, intense Y2 receptor positive fiber staining was
contrasting with relatively few NPY-GFP positive fibers
in the CEm (Fig. 5h–j), further suggesting that Y2
receptors are expressed by a higher number of neurons
and fibers in the CEm than its corresponding ligand
NPY.
3380 Brain Struct Funct (2016) 221:3373–3391
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Y2 receptors in the intercalated nuclei
Consistent with a presynaptic localization, Y2 receptor IR
was absent from the mITC and lITC (Fig. 5a–c) but weakly
expressed in the Im and strongly expressed in the adjacent
area of the CEm, the main projection target of the Im
(Fig. 5i, m). Interestingly, Y2 receptor positive fibers were
visible at the border between the BLA and CEA probably
connecting there the mITC with the Im (arrowheads in
Fig. 5b).
On the other hand, NPY-positive fibers were also
detected within the stria terminalis, the main output tract of
the amygdala (Fig. 6a, b), indicating the presence of NPY
projection neurons connecting the CEm with downstream
targets, such as the BNST. In the stria terminalis, NPY and
Y2 receptors display a similar distribution, but the
respective fibers were rather oriented in a parallel fashion
than displaying real co-localization (Fig. 6c–e). An addi-
tional source of NPY was provided here by neurons within
the supracapsular part of the stria terminalis (arrow in
Fig. 6d). There, NPY-GFP-positive neurons were residing
predominantly in the ‘‘medial and lateral pocket’’ extend-
ing their axons with many varicosities diagonal to the
projecting fibers of the stria terminalis (arrowheads in
Fig. 6d).
Neuronal tract tracing of NPY neurons
within the central extended amygdala
A subgroup of NPY neurons in the CEm co-labeled with
CR (Fig. 2l–o) and both, CR and NPY were also observed
in the stria terminalis (Fig. 6a–b), indicating that NPY/CR
neurons of the CEA are projecting to other brain areas. To
investigate in more detail the connectivity of NPY-ex-
pressing projection neurons in the central extended amyg-
dala (CEA and BNST), we injected the retrograde neuronal
tract tracer hydroxystilbamidine (Fluorogold, FG) into the
CEm (Fig. 7a–d) or BNST (Fig. 7e–h) of NPY-GFP mice,
bFig. 3 Expression of NPY in the main intercalated nucleus. a–
c NPY-GFP immunoreactivity indicates at least two types of NPY
neurons within the, Im: the majority of neurons exhibit relatively low
levels of NPY expression while a second group consists of
predominantly bipolar neurons with higher NPY expression. a–
f The majority of NPY-expressing neurons in the Im seem to express
also dopamine D1 receptor (D1R) (note the dense packing of NPY-
GFP neurons in the Im that makes identification of individual neurons
difficult). d–f Higher magnification image depicting NPY-GFP
expression in the soma and dendrites and D1R expression frequently
co-localizing with NPY-GFP-positive somata and dendritic fibers,
examples are indicated by arrows. g–h whole-cell current-clamp
recordings obtained in the presence of glutamate and GABA receptor
antagonists (DL-AP5, DNQX and picrotoxin, to block synaptic
transmission) demonstrated that application of the D1R agonist,
A68930, reversibly hyperpolarizes Im neurons (paired t test:
t(5) = 4.16, p\ 0.01; n = 6 cells from 6 slices from 5 mice). i–k
Dual immunohistochemistry for NPY-GFP and SST illustrating a
second group of NPY-expressing neurons in the Im. l–n Higher
magnification of dual-labeled SST/NPY-GFP neurons that are located
within and around the NPY-GFP cell cluster of the Im. Scale bars a–
c, j–k 200 lm and d–f, l–n 20 lm
Fig. 4 Validation of Y2 receptor antibody and immunohistochem-
istry procedure. a, e Photomicrograph of a Y2 receptor immunohis-
tochemistry on a coronal section of a mouse brain depicting the dorsal
hippocampus and the amygdala displays similar distribution as b,
f autoradiograph of a receptor binding with the Y2 preferring agonist
[125I]PYY3-36. c, g Corresponding in situ hybridization for Y2
receptor mRNA demonstrating compatible distribution with Y2
receptor immunohistochemistry and supporting the presynaptic
expression of Y2 receptors. d, h However, absence of Y2 receptor
binding and immunohistochemical labeling for Y2 receptors in a
Y2KO mouse. (Note the unspecific staining of nuclei and somata in
the Y2KO mouse frequently misinterpreted as Y2 receptor labeling).
Scale bars 500 lm
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followed by dual immunofluorescence for FG and NPY-
GFP (Fig. 8a, f). FG was co-localized with NPY-GFP in
the BNST (Fig. 8b–e) as well as in the CEm (Fig. 8g–j)
after injection of FG into the CEm and BNST, respectively,
suggesting that NPY-expressing neurons are projecting
from the CEA to the BNST and also backwards from the
Fig. 5 Expression of Y2 receptors (green) and NPY (red) in the
central (CEA) and basolateral amygdala (BLA). a–c Dual labeling of
Y2 receptor and nuclear staining (blue, Hoechst 33342) in the CEA
and BLA. Y2 receptors are expressed predominantly in the centro-
medial (CEm), but not in the centrolateral amygdala (CEl). Note the
relative absence of Y2 receptor expression in the lateral (lITC) and
medial (mITC) intercalated cells compared to the high expression in
the main intercalated nucleus (Im). Similar to NPY-GFP expression,
Y2 receptor expressing fibers connect the mITC and Im (arrowheads).
d–f Y2 receptor expression is shown in afferent and efferent
connections of the Im at higher magnification, nuclear staining in
blue (Hoechst 33342) and g higher magnification image demonstrat-
ing that Y2 receptor immuno-positive puncta are surrounding the blue
cell nuclei in the CEm. h–j Dual labeling of NPY-GFP and Y2
receptor immunoreactivity in the anterior part of the CEA, note the
high expression of NPY-GFP in the Im and the absence of co-labeling
of Y2 receptor and NPY-GFP. k High magnification photomicrograph
demonstrating that Y2 receptors (blue arrows) and NPY-GFP (white
arrows) do not co-localize in the same fibers but rather Y2 receptors
are bordering cell somata (asterisks) and are surrounded by NPY-GFP
fibers. l–n Higher magnification depicting non-overlapping expres-
sion of NPY-GFP and the Y2 receptor in the Im (Abbreviation: CEc,
capsular nucleus of the central amygdala) and o higher magnification
image of the border between Im and CEm with high expression of
NPY-GFP and Y2 receptors in the Im and CEm, respectively. Note
that immuno-labeling for Y2 receptors (blue arrows) and NPY-GFP
(white arrows) are surrounding cell bodies (asterisks), but do not co-
localize. Scale bars a–c, d–f, h–j, l–m 100 lm and in g for g, k,
o 20 lm
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BNST to the CEA (Tables 4, 5). Specifically, neuronal
tract-tracing results indicated that 7.7 % (4/56) and 8.1 %
(5/62) of NPY-GPF neurons in the lateral and medial
BNST, respectively, project to the ipsilateral CEA. Inter-
estingly, a minor population of NPY-GFP neurons, 1.6 %
(1/64) and 4.1 % (2/49) of the lateral and medial BNST,
respectively, project to the contralateral CEA (Table 4). On
the other hand, 4.3 % of NPY-GFP neurons (6/139) of the
CEm are projecting to the ipsilateral BNST. No projections
of NPY neurons originated from the CEl and none of the
NPY-GFP neurons in the CEA projected to the contralat-
eral BNST. However, 25.8 % (8/31) of NPY-GFP neurons
located within the medial and lateral pocket of the stria
terminalis projected to the ipsilateral BNST (Table 5).
Thus, NPY may be released within the central extended
amygdala not only from local SST containing interneurons
in the CEm, BNST and stria terminalis, but also from
projection neurons connecting the CEm with the BNST and
vice versa the BNST with the CEm.
Role of Y2 receptors on inhibitory synaptic
transmission in the CEm
We next investigated the functional role of Y2 receptors in
the CEm by recording spontaneous inhibitory postsynaptic
currents (sIPSCs) before and after application of the Y2
receptor agonist PYY3-36 in the CEm of wildtype (WT),
NPYKO and Y2KO mice. Two-way ANOVA for repeated
measurements revealed a significant difference between
genotypes and treatment (Fig. 9a–c, genotype: F(2/
14) = 6.69, p\ 0.01, treatment: F(1/14) = 23.96, p\ 0.001
and interaction: F(2/14) = 12.31, p\ 0.001). In WT mice,
neurons of the CEm exhibited sIPSCs with a mean fre-
quency of 1.3 Hz that was reduced by 37 % after bath
application of the Y2 receptor agonist, PYY3-36
(t(4) = 4.96, p\ 0.01; Fig. 9a, b). The amplitude of
sIPSCs was unaltered (Fig. 9c). To test the specificity of
PYY3-36 on Y2 receptors we next recorded sIPSCs in the
CEm of mice lacking the Y2 receptor (Y2KO). PYY3-36
did not alter the frequency or amplitude of events
(p[ 0.05; Fig. 9a–c), demonstrating its specificity, but
interestingly, the baseline frequency of sIPSCs was sig-
nificantly higher in Y2KO mice compared to WT mice
(one-way ANOVA with Bonferroni post hoc test: WT vs.
Y2KO: t(2) = 2.96, p\ 0.05; Fig. 9a, b). To investigate
this issue, we recorded sIPSCs in the CEm of NPYKO
mice. Baseline sIPSC frequency was higher in NPYKO
mice compared to WT, and similar to sIPSCs in Y2KO
mice (one-way ANOVA with Bonferroni post hoc test: WT
vs. NPYKO: t(2) = 2.84, p\ 0.05). Application of PYY3-
Fig. 6 Expression of NPY in
the stria terminalis. a NPY-
expressing neurons are present
in the CEm/BNST, note the
high density of NPY-positive
fibers in the stria terminalis.
b Two different types of NPY-
fibers are present in the stria
terminalis (st): type one are thin
and run parallel to the stria
terminalis, while type 2 (orange
arrowheads) are diagonally
oriented and display multiple
varicosities (white arrow
depicts an NPY neuron within
the stria terminalis). c–e Dual
labeling of Y2 receptors (red)
and NPY-GFP (green) in the
stria terminalis. Although Y2
receptors and NPY are running
in parallel, they do not co-
localize in individual fibers.
Note the NPY-GFP labeled
transverse axons with dense
varicosities (d, orange arrows).
Scale bar 200 lm
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36 significantly reduced the frequency of sIPSCs in
NPYKO mice (paired t test: t(5) = 6.67, p\ 0.01; Fig. 9b)
but had no effect on sIPSC amplitude (paired t test:
t(5) = 0.09, p[ 0.05, Fig. 9c). We hypothesized that the
increase in basal inhibition of the CEm in Y2KO and
NPYKO mice may be due to either spontaneous NPY
release in the slice or a result of germline deletion of NPY
or the Y2 receptor. To specifically address this issue we
recorded sIPSCs before and after application of the Y2
receptor antagonist, JNJ-3102002 (Fig. 9d–f). Bath appli-
cation of the Y2R antagonist had no effect on the frequency
(paired t test: t(8) = 0.18, p[ 0.05) or amplitude (paired
t test: t(8) = 0.81, p[ 0.05) of sIPSCs.
To test the hypothesis that Y2 receptors reduce the
frequency of sIPSCs in the CEm by a presynaptic mecha-
nism, we recorded electrically evoked IPSCs (eIPSCs;
Fig. 9g) in response to paired pulse stimulation of medial
inputs to the CEA, thought to arise from the BNST (De-
laney and Sah 2001). The amplitude of eIPSCs was sig-
nificantly reduced upon application of the Y2 receptor
agonist PYY3-36 (Fig. 9h, i), but overall we did not detect a
change in the paired pulse ratio (PPR, a measure of neu-
rotransmitter release probability). Specifically, the PPR
increased in 10 out of 14 neurons, consistent with a
presynaptic localization of Y2 receptors and a reduction in
GABA release probability; however, four neurons exhib-
ited a reduction in PPR (Fig. 9j) likely indicating a
heterogeneous input to the CEm. Taken together, applica-
tion of PYY3-36 in acute brain slices from WT mice
demonstrates that Y2 receptor activation reduces inhibitory
input to the CEm, while the increased frequency of sIPSCs
observed in Y2KO and in NPYKO mice indicates that Y2
receptor stimulation during pre- or postnatal development
significantly modulates inhibitory synaptic transmission.
Role of Y2 receptors on excitatory synaptic
transmission in the CEm
Together, the absence of co-localization of NPY-GFP and
Y2 receptors in the CEm (Fig. 5h–o) and the reduction of
sIPSC frequency upon application of PYY3-36 (Fig. 9)
suggest that predominantly presynaptic Y2 receptors serve
as hetero-receptors that reduce inhibitory input in the CEm.
However, excitatory inputs from the BLA and cortical
areas also target the CEm and may therefore also be reg-
ulated by NPY acting on presynaptic Y2 receptors. To
investigate the role of Y2 receptors on excitatory input to
the CEm, we recorded spontaneous excitatory postsynaptic
currents (sEPSCs) in CEm neurons under baseline condi-
tions and in the presence of PYY3-36 (Fig. 10a). As shown
Fig. 7 Verification of the injection site for the retrograde tracer
Fluorogold in BNST and CEA injected mice. a Atlas image depicting
the injection site for the CEA, b NPY-GFP fluorescence in the CEA,
c FG fluorescence and d overlay showing the injection site of the
retrograde neuronal tract tracer Fluorogold in a coronal section of an
NPY-GFP mouse brain. e Atlas image depicting the injection site for
FG in the BNST, f NPY-GFP endogenous fluorescence, g FG
fluorescence and h overlay depicting the injection site in the BNST in
a coronal section of an NPY-GFP mouse brain. Scale bar 100 lm.
Arrows indicate injection site
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in Fig. 10, application of the Y2 receptor agonist PYY3-36
significantly reduced the frequency of sEPSCs by 29 %
(paired t test: t(5) = 2.94, p\ 0.05; Fig. 10b, c) but did not
alter the amplitude (Fig. 10d), consistent with the presence
of presynaptic Y2 receptors on glutamatergic inputs to the
CEm. No difference was detected in Y2KO mice, con-
firming the specificity of the compound. In contrast to our
finding that sIPSC frequency was elevated in Y2KO mice,
no difference in sEPSC frequency was detected in Y2KO
mice under baseline conditions, suggesting that during
development Y2 receptors may have an important role in
fine-tuning, particularly, inhibitory synaptic transmission in
the CEm.
Discussion
Combining slice electrophysiology, neuronal tract-tracing
and immunohistochemistry, we provide evidence that NPY
and Y2 receptors are ideally positioned to fundamentally
shape CEA output. Specifically we demonstrated that Y2
receptor activation attenuates GABA as well as glutamate
Fig. 8 Neuronal tract tracing of NPY-expressing neurons in the
central extended amygdala. a Injection of the retrograde tracer
Fluorogold (FG) into the centromedial amygdala (CEm). b–d Dual
immunofluorescence of NPY-GFP and the retrograde neuronal tracer
FG in the bed nucleus of the stria terminalis (BNST) demonstrating
that NPY-positive neurons are projecting from the BNST to the CEm.
e Higher magnification image of dual-labeled cells expressing NPY-
GFP and FG (white arrows) in the BNST. f Injection of the retrograde
tracer FG into the BNST of NPY-GFP mice and g–i dual
immunohistochemistry of NPY-GFP and FG in the CEm, demon-
strating that NPY-GFP neurons project from the CEm to the BNST.
j Higher magnification of a dual-labeled cell for NPY-GFP and FG in
the CEm. k–m Dual immunofluorescence of NPY-GFP and FG in the
stria terminalis (st), illustrating the presence of NPY neurons in the
medial pocket of the st that are targeting the BNST. n Higher
magnification image of a dual-labeled cell expressing NPY-GFP and
FG in the st. BNST-AL anterior lateral region of the BNST. Scale bars
b–d, g–i, k–m 100 lm and in j for e, j, n 20 lm





Percent of NPY-GFP? neurons
double-labeled with FG
BNST lateral ipsi 52 4 7.69 % (4/56)
BNST lateral contra 62 1 1.56 % (1/64)
BNST medial ipsi 57 5 8.06 % (5/62)
BNST medial contra 47 2 4.08 % (2/49)
Stria terminalis ipsi 66 1 1.49 % (1/67)
Stria terminalis contra 69 0 0 % (0/69)
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release after activation by exogenously applied PYY3-36.
Interestingly, germline deletion of Y2 receptors resulted in
a baseline increase of sIPSCs but not in sEPSCs in the
CEm, suggesting an important role of Y2 receptors during
establishment of inhibitory synapses. Using immunohisto-
chemistry we found that NPY is expressed by multiple
populations of neurons in the CEA, BNST and Im, while
the Y2 receptors are also located on afferent and/or efferent
projections.
Compared to other amygdala nuclei, the highest levels
of Y2 receptors are found in the CEA and BNST. These Y2
receptors may be present primarily on local circuit neurons;
however, our observation of dense Y2 receptor labeling
within the stria terminalis suggests that the Y2 receptor is
also expressed by GABAergic, NPY-negative projection
neurons. As shown previously by receptor binding, Y2
receptors are located on axon terminals of CEA neurons
targeting the BNST, hypothalamus and brainstem (Tasan
et al. 2010), suggesting that NPY modulates GABAergic
projections originating from the CEA. In particular, the
lateral part of the anterior BNST that harbors predomi-
nantly GABAergic neurons (Poulin et al. 2009) receives
dense projections from the CEA (Dong et al. 2001) and is
involved in the mediation of anxiolytic-like behavior
(Gungor and Pare 2014; Jennings et al. 2013; Sink et al.
2011). Thus, Y2 receptors that reduce GABA release from
CEA projections may modulate anxiety-like behavior by
disinhibiting CEA projection targets, such as the anterior
BNST. Neuropeptides are preferentially released upon
strong, high-frequency stimulation. Thus, fearful situations
that strongly activate NPY neurons may cause NPY release
and result in a time-lagged but prolonged action of NPY
limiting an otherwise excessive fear response (Heilig et al.
1994; Heilig 2004).
Several lines of evidence indicate that Y2 receptors
reduce inhibition of the CEm by a presynaptic mechanism.
First, application of PYY3-36 reduced the frequency, but not
the amplitude of sIPSCs in WT and NPYKO mice. Fur-
thermore, an increase in the PPR of eIPSCs (in 10 out of 14
cells) electrically evoked at GABAergic projections medial
to the CEm, suggests that activation of presynaptic Y2
receptors reduces GABA release probability in the CEm.
These CEm targeting GABAergic terminals that contain
Y2 receptors and/or NPY, likely arise from different
locations, such as BNST or hypothalamus. However, we
did not observe immunohistochemical co-labeling of Y2
receptors and NPY, suggesting that the concept of Y2
receptors as auto-receptors (Broberger et al. 1997) regu-
lating and limiting NPY release does not hold true for the
central extended amygdala (Stanic et al. 2011). We rather
propose Y2 receptors as hetero-receptors that are expressed
locally and on afferent and efferent projections of the CEm,
while NPY is provided by multiple sources within this
system. For instance, NPY is predominantly expressed by
SST-containing interneurons in the CEm and stria termi-
nalis (Table 2). Thus, Y2 receptor containing afferent and
efferent projections in the CEm are surrounded by NPY-
expressing interneurons that may provide an important
source of NPY for long-term suppression of synaptic
activity (Fig. 11). In addition, NPY is also expressed by
CEA projection neurons, BNST to CEm back-projections
as well as by neurons that are located within the stria ter-
minalis (Tables 4, 5). Some of the latter are even targeting
the BNST. Both, NPY and CR were present in the stria
terminalis, the main output fiber tract of the CEm, sug-
gesting that NPY/CR neurons are projection neurons. On
the other hand, SST-IR was not detected in the stria ter-
minalis, indicating that NPY/SST neurons in the CEm are
local circuit neurons. However, recent evidence suggests
the existence of NPY/SST projection neurons in the
basolateral amygdala of the rat (McDonald and Zaric 2015;
McDonald et al. 2012). Further experiments are needed to
investigate the phenotype of NPY/SST neurons also for the
CEA and BNST.
Recent studies have demonstrated that Y2 receptor
activation attenuates mIPSC frequency in the BNST (Kash
and Winder 2006; Pleil et al. 2012). Here, we demonstrate
a reduction of sIPSCs and sEPSCs in the CEm upon acti-
vation of the Y2 receptor. Interestingly, baseline sIPSCs
but not sEPSCs in the CEm were equally increased in
Y2KO and NPYKO mice, suggesting constitutive activa-
tion of Y2 receptors by NPY on GABAergic neurons in
WT mice, a phenomenon that has been described for the
mossy fiber pathway previously (Tu et al. 2005). On the





Percent of NPY-GFP? neurons
double-labeled with FG
Centrolateral ipsi 21 0 0 % (0/21)
Centrolateral contra 26 0 0 % (0/26)
Centromedial ipsi 133 6 4.32 % (6/139)
Centromedial contra 115 0 0 % (0/115)
Stria terminalis ipsi 23 8 25.81 % (8/31)
Stria terminalis contra 8 1 11.10 % (1/9)
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other hand, bath application of the Y2 receptor antagonist
JNJ-31020028 on acute brain slices of WT mice did not
change sIPSCs, inconsistent with tonic release of NPY in
the CEA. Rather the absence of NPY and Y2 receptors
during embryonic or postnatal development may lead to a
constitutive, increased activation of GABAergic, but not
glutamatergic projections in the CEA. This speaks against a
tonic release of NPY in the CEA, but highlights the
importance of NPY and Y2 receptors during development
for establishing the necessary connectivity of emotion-
relevant pathways. In support of this notion, Y5KO mice
are insensitive to NPY at excitatory mossy-fiber CA3
synapses (Guo et al. 2002). Further studies are warranted to
elucidate this altered connectivity in NPYKO and Y2KO
mice. There are certainly limitations to what extent a slice
preparation can recapitulate in vivo physiology, thus fur-
ther studies using in vivo electrophysiology are needed to
substantiate the current data. Neuropeptides are released at
relatively low concentrations and during periods of high-
frequency firing, but display high receptor affinity and
prolonged duration of action. NPY generally acts on dif-
ferent Y receptors (Y1, Y2, Y5) and may diffuse within the
central extended amygdala and along the stria terminalis by
volume transmission acting there on Y2 receptors
Fig. 9 Y2 receptor activation reduces GABAergic input to CEm
neurons. a Representative traces of sIPSCs recorded in WT, Y2KO
and NPYKO mice before and after PYY3-36 application. b–c PYY3-36
reduces the frequency but not amplitude of sIPSCs (note the increased
baseline frequency of sIPSCs in Y2KO and NPYKO mice compared
to WT) (**paired t test, p\ 0.01; *one-way ANOVA, p\ 0.05;
n = 5 cells from 5 slices from 3 mice WT, 6 cells from 6 slices from
3 mice Y2KO and 6 cells from 6 slices from 4 mice NPYKO).
d Representative traces of sIPSCs recorded prior to, and after JNJ-
31020028 application. e–f The Y2R antagonist, JNJ-31020028, did
not alter the frequency or amplitude of sIPSCs in the CEm (paired
t test, p[ 0.05, n = 9 cells from 9 slices from 4 mice). g Schematic
of the recording configuration. h Representative traces of medially
evoked IPSCs in CEm neurons of WT mice before and after PYY3-36.
i–j PYY3-36 reduced the amplitude of eIPSCs (paired t test, p\ 0.01)
but did not significantly alter the PPR, although the majority of cells
revealed an increase in PPR (10 out of 14 cells, boxed area; n = 14
cells from 14 slices from 7 mice)
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potentially generating a prolonged inhibitory action by
reducing the activity of long-distance fiber tracts. However,
not all afferent GABAergic terminals targeting the CEm
are Y2 receptor positive, as indicated by the heterogeneous
response to PYY3-36 observed using electrical stimulation.
Interestingly, PYY3-36 also decreased the frequency of
sEPSCs and in contrast to sIPSCs, the baseline frequency
of sEPSCs was not altered in Y2KO mice. While inhibitory
fibers may originate from adjacent intercalated cell masses,
the BNST or from local interneurons, the origin of exci-
tatory inputs that express presynaptic Y2 receptors is not
yet clear. However, in particular, the prefrontal cortex
contains significant amounts of Y2 receptor expressing
neurons (Stanic et al. 2006, 2011) and targets both the CEm
as well as the BNST (Bienkowski and Rinaman 2013).
Future experiments are required to identify the origin of
GABAergic and glutamatergic CEm afferents that are
modulated by NPY and Y2 receptors.
It is important to note that PYY3-36 does not exclusively
act on Y2 receptors, but is in fact also a potent agonist of
the Y5 receptor. In this regard, Sajdyk et al. (2002) have
suggested that in the basolateral amygdala of the rat Y2
receptor stimulation results in an anxiogenic phenotype,
whereas activation of Y5 receptors is anxiolytic (Sajdyk
et al. 2002). However, in the present study application of
PYY3-36 on slices from Y2KO mice did not alter sIPSCs or
sEPSCs, suggesting that, at least in the CEA, Y2 receptors,
and not Y5 receptors lead to the observed reduction in
synaptic transmission.
Fig. 10 PYY3-36 reduces
excitatory input to CEm neurons
in WT mice. a Schematic of the
recording location.
b Representative traces of
sEPSCs recorded in the
presence of the GABAA
receptor antagonist picrotoxin
(Ptx). c–d PYY3-36 reduced the
frequency (*paired t test,
p\ 0.05) but not amplitude of
sEPSCs in CEm neurons, and
had no effect on excitatory
synaptic transmission in cells
recorded from Y2KO mice
(n = 6 cells from 6 slices from
3 WT mice; 5 cells from 5 slices
from 3 Y2KO mice)
Fig. 11 Schematic of Y2 receptor (Y2R) distribution and different
sources of NPY in the central amygdala. NPY is expressed in CEm
neurons (NPY/somatostatin/GABA) and in CEm afferences (NPY/
GABA). GABAergic projections from NPY-expressing intercalated
neurons of the Im, NPY/dopamine D1 receptor (D1R/GABA), may
also be a source of NPY. The Y2 receptor is highly expressed in the
CEm on both excitatory and inhibitory inputs. Thus, NPY-Y2R
signaling may provide dynamic modulation of CEm activity
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Previous evidence suggests that Y2 receptor stimulation
promotes anxiety (Bacchi et al. 2006; Nakajima et al. 1998;
Redrobe et al. 2003; Tasan et al. 2010; Tschenett et al.
2003), but see also Kask et al. (1998). However, evidence
from NPY and Y receptor KO mice suggests that Y2
receptor activation may reduce expression of conditioned
fear while promoting fear extinction (Verma et al. 2012).
Different brain circuits are involved in fear and anxiety
(Davis et al. 2010; Walker and Davis 1997; Walker et al.
2003) and Y2 receptors may play different roles in the
respective circuitries. For instance, it may be possible that
Y2 receptors located on glutamatergic and GABAergic
terminals in the CEA differentially affect fear and anxiety-
related behaviors, respectively. However, addressing this,
and similar concepts will require further investigation.
In summary, we have identified multiple populations of
NPY-expressing neurons within or adjacent to the central
extended amygdala (Fig. 11). While NPY is predominantly
expressed by SST-expressing neurons, we have identified
several other important NPY-expressing neuronal subtypes.
These include, CR-expressing neurons of the CEm, D1
receptor expressing neurons of the Im and SST-expressing
neurons in the Im. Furthermore, we provide evidence that
NPY neurons reciprocally connect the CEm with the BNST
and some of these are located within the stria terminalis.
Lastly, we have shown that NPY acting on Y2 receptors
modulates inhibitory and excitatory signaling in the CEm.
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